Dow AgroSciences | GenomeWeb

Dow AgroSciences

The technology is based on engineered zinc finger DNA-binding proteins, which bind to specific functional domains to create transcription factors capable of activating or repressing target genes.

The funding will support support two alliances between industry and academia that are applying genomic technologies to agriculture and healthcare.

The deal expands the companies' ongoing collaboration, which began in mid-2015, to include additional natural product targets in crop protection and traits.

Critical Path will license Dow AgroScience's Plextein technology for multiplex detection of plant proteins using mass spectroscopy and provide it as a service.

The company will work with the Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences to develop the technology into a rice genome-editing platform.

In the study, company researchers explored treating corn rootworms with RNAi molecules that would interfere with the viability of their offspring.

The companies will work together to discover and develop natural products for crop protection.

NEW YORK (GenomeWeb) – In Nature Genetics, an international team led by investigators at the National Institute on Aging presented findings from a meta-analysis of Parkinson's disease genome-wi

NEW YORK (GenomeWeb) – Dow AgroSciences said today that Sigma-Aldrich will manufacture and supply zinc finger nuclease reagents for use with Dow AgroSciences' Exzact Precision Technology, a genome modification platform for plants.

While chemical proteomics has traditionally focused on pharmaceutical work, several recent collaborations suggest that the field is establishing a foothold within agricultural research, as well.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.